MEDVi QUAD Review: 4-in-1 with Apomorphine - What to Know Before Buying

MEDVi is a telehealth platform offering a compounded prescription ED medication called QUAD, a 4-in-1 sublingual formulation combining sildenafil, tadalafil, vardenafil, and apomorphine. MEDVi launched in September 2024 and has grown rapidly in the ED telehealth market.

Sildenafil, tadalafil, and vardenafil are individually FDA-approved for the treatment of erectile dysfunction. Apomorphine is FDA-approved for other indications and is used off-label in this context. MEDVi QUAD is a compounded medication and is not FDA-approved as a finished drug product.

This article reviews MEDVi's ED offering, how it works, what it contains, its cost, and its pros and cons.

This article is for informational purposes only and should not be taken as medical advice. If you have questions or concerns about your condition or treatment, please consult a healthcare provider.

What Is MEDVi?

What it is: MEDVi is a direct-to-consumer telehealth platform offering prescription compounded ED medication through an online consultation process. After completing an intake form, a licensed clinician reviews your information and, if appropriate, issues a prescription that is filled by a compounding pharmacy and shipped to your door.

What it offers for ED: MEDVi currently offers one ED product, QUAD, a 4-in-1 sublingual liquid combining sildenafil, tadalafil, vardenafil, and apomorphine.

How much it costs: MEDVi QUAD is priced at approximately $10 to $12 per dose depending on the plan selected. Full pricing details are available on the MEDVi website after completing the intake process.

Pros: Four active ingredients in one dose; sublingual liquid delivery for faster absorption; addresses both physical blood flow and neurological arousal; all four ingredients individually studied; includes ongoing clinician oversight.

Cons: Compounded medication not FDA-approved as a finished product; three PDE5 inhibitors combined in one dose require careful prescriber oversight; not suitable for all patients; newer company with a shorter track record than established platforms.

Good for: Men who have not achieved adequate results from single-ingredient ED medications and are looking for a multi-mechanism approach under clinician supervision.

Not ideal for: Men new to ED treatment who have not yet tried standard single-ingredient sildenafil or tadalafil; men with cardiovascular conditions or those on certain medications that interact with PDE5 inhibitors.

MEDVi's ED Product: QUAD

QUAD is MEDVi's flagship product, a compounded sublingual liquid designed to address erectile dysfunction through four active ingredients working across different mechanisms simultaneously.

Active ingredients:

• Sildenafil (the active ingredient in Viagra): A PDE5 inhibitor that increases blood flow to the penis by blocking the enzyme that breaks down cGMP. Known for faster onset among PDE5 inhibitors.
• Tadalafil (the active ingredient in Cialis): A PDE5 inhibitor with a significantly longer half-life than sildenafil, supporting effects for up to 36 hours.
• Vardenafil (the active ingredient in Levitra): A PDE5 inhibitor with high selectivity for the PDE5 enzyme. May benefit men with diabetes or vascular conditions where other PDE5 inhibitors have been less effective.
• Apomorphine: A dopamine agonist that works on the central nervous system rather than through vascular pathways. It is thought to enhance the brain's arousal response, addressing the neurological component of sexual function that PDE5 inhibitors alone do not target.

Formulation: Sublingual liquid (placed under the tongue for absorption through the mucous membranes)

How to take it: Administered under the tongue before sexual activity, as directed by your prescribing clinician

How fast it works and how long it lasts: Sublingual delivery bypasses first-pass metabolism in the liver, theoretically allowing faster absorption than swallowed tablets. Sildenafil and vardenafil provide faster-onset effects; tadalafil extends duration up to 36 hours.

A note on combining PDE5 inhibitors: QUAD combines three PDE5 inhibitors in a single formulation. While each ingredient is individually FDA-approved, the combination as a finished product has not been FDA-evaluated. Combining multiple PDE5 inhibitors increases potency and the potential for dose-related side effects. This makes proper clinician evaluation and dosage calibration particularly important before starting QUAD.

How Does MEDVi QUAD Work?

QUAD addresses erectile dysfunction through two distinct pathways.

The three PDE5 inhibitors, sildenafil, tadalafil, and vardenafil, all work by blocking the phosphodiesterase type 5 enzyme, which normally breaks down cyclic GMP (cGMP) in penile blood vessels. By inhibiting PDE5, these medications allow cGMP to accumulate, relaxing smooth muscle and increasing blood flow to the penis during sexual stimulation. Sildenafil and vardenafil provide faster onset; tadalafil provides extended duration.

Apomorphine works through a separate mechanism entirely. As a dopamine agonist, it acts on the brain's dopaminergic pathways, which play a role in sexual arousal and desire. In clinical research, apomorphine has been studied for its ability to support the neurological component of arousal rather than addressing blood flow. The combination of blood-flow support from the PDE5 inhibitors and central arousal support from apomorphine is the defining characteristic of the QUAD formulation.

Side Effects of MEDVi QUAD

Because QUAD combines three PDE5 inhibitors, its potential side effect profile is similar to that of individual PDE5 inhibitors but may be more pronounced due to the combined potency. All side effects should be discussed with your prescribing clinician before starting.

Common side effects of PDE5 inhibitors:

• Headache
• Flushing
• Nasal congestion
• Dizziness
• Upset stomach or indigestion
• Muscle or back pain
• Temporary vision changes

Apomorphine-related side effects:

• Nausea (most common with apomorphine)
• Dizziness
• Yawning
• Low blood pressure

Rare but serious side effects:

• Sudden hearing or vision loss
• Severely low blood pressure
• Priapism (a prolonged erection lasting more than four hours) requires immediate medical attention

PDE5 inhibitors should not be combined with nitrate medications, other ED drugs not prescribed as part of the same protocol, or certain blood pressure medications. Men with cardiovascular conditions should discuss their full medical history with a provider before starting QUAD.

How to Get a MEDVi Prescription

The process is fully online:

1. Complete an online medical intake form on the MEDVi website
2. A licensed clinician reviews your intake information
3. If appropriate, a prescription is issued and filled by a licensed compounding pharmacy
4. Your medication is shipped discreetly to your door

How Much Does MEDVi Cost?

MEDVi QUAD is priced at approximately $10 to $12 per dose. Full pricing is presented during the consultation process on the MEDVi website.

For reference, single-ingredient generic ED medications (sildenafil or tadalafil) from telehealth providers typically range from $2 to $10 per dose. QUAD's price reflects its multi-ingredient compounded format and bundled consultation management.

Health insurance is not accepted.

MEDVi Reviews and Reputation

MEDVi is a newer platform, having launched in late 2024. The company has grown quickly in the ED telehealth market, with its QUAD product gaining attention as one of the few 4-in-1 compounded ED formulations available. Customer reviews of the product itself are generally positive among men who report trying it after finding single-ingredient options insufficient.

Prospective customers should review MEDVi's current terms, policies, and any regulatory updates on the MEDVi website before enrolling, as the company is relatively new and the landscape around it is still developing.

Who Is MEDVi For?

MEDVi QUAD may be worth considering for men who:

• Have tried standard single-ingredient sildenafil or tadalafil and found results inconsistent or insufficient
• Want a multi-mechanism approach that addresses both the physical blood flow component and the neurological arousal component of ED
• Are comfortable with compounded medications and the telehealth prescription model
• Are under clinician supervision with appropriate cardiovascular health for PDE5 inhibitor use

Who May Not Want to Choose MEDVi?

• Men who are new to ED treatment and have not yet tried single-ingredient monotherapy
• Men with cardiovascular conditions, those on nitrates, or those on blood pressure medications that interact with PDE5 inhibitors
• Men who prefer FDA-approved finished drug products only

Is MEDVi QUAD FDA-Approved?

No. MEDVi QUAD is a compounded medication. The individual active ingredients, sildenafil, tadalafil, and vardenafil, are FDA-approved for ED treatment when prescribed individually. Apomorphine is FDA-approved for other indications. The 4-in-1 compounded combination as a finished product has not been FDA-evaluated for safety, efficacy, or quality.

MEDVi Pros and Cons

Pros

• Four-ingredient formulation: Combines three PDE5 inhibitors and apomorphine to address both vascular and neurological components of ED
• Sublingual liquid delivery: Designed for faster absorption than swallowed tablets
• Clinician oversight included: Prescription requires licensed clinician review
• Multi-mechanism approach: Addresses ED through multiple pathways simultaneously

Cons

• Compounded medication: Not FDA-approved as a finished product
• Three PDE5 inhibitors combined: Higher combined potency requires careful prescriber calibration; not appropriate for all patients
• Newer platform: Less of a track record compared to established telehealth providers
• Higher per-dose cost: At approximately $10 to $12 per dose, QUAD costs more than standard single-ingredient generics

Alternatives to MEDVi for ED

For men interested in a sublingual combination ED treatment with clinician oversight, Rugiet Ready is a sublingual lozenge combining sildenafil, tadalafil, and apomorphine in four dose tiers. Rugiet Ready offers the option to start at a lower strength and adjust as needed, which may be relevant for men who want to titrate carefully before moving to a higher-potency formulation. Visit rugiet.com to learn more.

Bottom Line

MEDVi's QUAD product represents a multi-ingredient approach to ED treatment, combining three PDE5 inhibitors and apomorphine in a single sublingual dose. A few things worth knowing before you start:

• QUAD is not for men new to ED treatment. It is a high-potency compounded formulation best suited to men who have already tried and found single-ingredient options insufficient.
• Clinician evaluation matters more here than with standard generics. Combining three PDE5 inhibitors requires careful assessment of cardiovascular health and current medications.
• MEDVi is a newer company. Review current policies and any regulatory developments before enrolling.

If you are considering a sublingual combination ED treatment and want to start with dosage flexibility, Rugiet Ready offers four strength tiers as an alternative worth exploring.